Scientists Race To Perfect New Oral COVID-19 Treatment Poised To Replace Paxlovid

Rutgers researchers are advancing a potential new COVID-19 treatment, Jun12682, which is effective in animal studies and compatible with other medications, unlike the current leading treatment, Paxlovid.
Researchers at Rutgers believe they are among the lead in developing an oral COVID-19 treatment that could supplement or replace Paxlovid, an antiviral drug that aids in preventing hospitalizations among high-risk patients.

Their report, published in the journal Science, shows that an alternative medication, a viral papain-like protease inhibitor, inhibits disease progression in animals, a necessary step before human drug trials.